09.10.2019 • NewsCelaneseElaine Burridge

Celanese Mulls Breakup in Strategic Review

Celanese Mulls Breakup in Strategic Review (c) Celanese
Celanese Mulls Breakup in Strategic Review (c) Celanese

US specialty materials company Celanese is undertaking a strategic review that could include a breakup, people familiar with the matter told Bloomberg.

The Dallas, Texas-based group is working with a financial advisor, and the review is said to be at an early stage. No final decision has been made and Celanese could decide against a break-up, the sources said.

Should Celanese opt to split, it would be the latest large chemicals group to undergo a strategic transformation, according to the news agency.

Celanese has six business units: engineered materials, cellulose derivatives, intermediate chemistry, food ingredients, EVA polymers and emulsion polymers.

In an Oct. 1 research report, US-based Zacks Equity Research said that while Celanese is poised to benefit from productivity measures, growth investments in organic projects and strategic acquisitions, it is facing a “challenging business environment.” The company is exposed to sluggish demand, partly due to weakness across Europe and Asia, with consumption also slowing down across several end markets in the second quarter, especially automotive and electronics, Zacks said.

In addition, lower demand in the quarter has hurt sales in its engineered materials and acetyl chain businesses. In its acetate tow segment, where low utilization rates are affecting volumes and demand remains subdued, the company is under pressure.

For second-quarter 2019, Celanese reported net income down 39% year-on-year at $210 million, with sales down 14% to $1.6 billion.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.